Deep Learning as an Opportunity in Virtual Screening
暂无分享,去创建一个
[1] L. Kier. Molecular Orbital Theory In Drug Research , 1971 .
[2] Rich Caruana,et al. Multitask Learning , 1998, Encyclopedia of Machine Learning and Data Mining.
[3] Shu-Kun Lin. Pharmacophore Perception, Development and Use in Drug Design. Edited by Osman F. Güner , 2000 .
[4] Darren V. S. Green,et al. Prediction of Biological Activity for High-Throughput Screening Using Binary Kernel Discrimination , 2001, J. Chem. Inf. Comput. Sci..
[5] Jens Sadowski,et al. Comparison of Support Vector Machine and Artificial Neural Network Systems for Drug/Nondrug Classification , 2003, J. Chem. Inf. Comput. Sci..
[6] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[7] Xiaoyang Xia,et al. Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.
[8] A. Bender,et al. In silico target fishing: Predicting biological targets from chemical structure , 2006 .
[9] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[10] Andreas Bender,et al. Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..
[11] Yanli Wang,et al. PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .
[12] J. Mestres,et al. A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.
[13] Michael J. Keiser,et al. Off-target networks derived from ligand set similarity. , 2009, Methods in molecular biology.
[14] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[15] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[16] Geoffrey E. Hinton,et al. Rectified Linear Units Improve Restricted Boltzmann Machines , 2010, ICML.
[17] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[18] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[19] Robert C. Glen,et al. Classifying Molecules Using a Sparse Probabilistic Kernel Binary Classifier , 2011, J. Chem. Inf. Model..
[20] Yoshua Bengio,et al. Deep Sparse Rectifier Neural Networks , 2011, AISTATS.
[21] J. Arrowsmith. Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.
[22] P. Willett,et al. PHARMACOPHORE PERCEPTION , DEVELOPMENT , AND USE IN DRUG DESIGN , 2011 .
[23] Nitish Srivastava,et al. Improving neural networks by preventing co-adaptation of feature detectors , 2012, ArXiv.
[24] John B. O. Mitchell,et al. Predicting the mechanism of phospholipidosis , 2012, Journal of Cheminformatics.
[25] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[26] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[27] Robert C. Glen,et al. Full “Laplacianised” posterior naive Bayesian algorithm , 2013, Journal of Cheminformatics.
[28] Pascal Vincent,et al. Representation Learning: A Review and New Perspectives , 2012, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[29] Geoffrey Zweig,et al. Recent advances in deep learning for speech research at Microsoft , 2013, 2013 IEEE International Conference on Acoustics, Speech and Signal Processing.
[30] Yoshua Bengio,et al. Deep Learning of Representations: Looking Forward , 2013, SLSP.
[31] P. Baldi,et al. Deep Learning in High-Energy Physics: Improving the Search for Exotic Particles , 2014 .
[32] Michael Hay,et al. Clinical development success rates for investigational drugs , 2014, Nature Biotechnology.